NCT03856216 2026-04-15
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
56 trialsNCT01661881 2026-04-08
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT03834688 2025-08-11
PrE0405
PrECOG, LLC.
Phase 2 Completed
NCT03739619 2025-08-06
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Emory University
Phase 1/2 Completed
NCT03872180 2025-08-06
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Emory University
Phase 2 Active not recruiting
NCT04217317 2025-05-02
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01458366 2025-04-30
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
Phase 1/2 Completed
NCT02224729 2025-04-30
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Thomas Jefferson University
Phase 2 Completed
NCT01437709 2025-02-28
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03187223 2025-01-30
BEB-2
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT03311126 2024-10-24
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
University of Wisconsin, Madison
Phase 2 Terminated
NCT02002598 2024-09-19
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Phase 1/2 Terminated
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT01664910 2024-07-23
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT01177683 2023-10-06
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT01754857 2023-06-27
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
University of Wisconsin, Madison
Phase 2 Completed
NCT02257242 2023-02-09
BRiM
Brown University
Phase 1 Completed
NCT02853370 2023-02-01
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT04155840 2022-04-11
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Washington
Phase 2 Terminated
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT01535924 2021-11-19
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT01234766 2021-05-18
Fol-BRITe
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02059239 2021-02-21
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT02477215 2020-10-22
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1/2 Completed
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00901927 2020-04-03
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01222260 2020-03-30
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Phase 2 Completed
NCT01491841 2020-03-04
BRP
Duke University
Phase 1 Completed
NCT01438177 2020-02-24
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
Phase 2 Terminated
NCT01049945 2020-02-11
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00899431 2020-01-27
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00974233 2019-12-02
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
University of Wisconsin, Madison
Phase 2 Completed
NCT01096992 2019-09-25
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00916058 2019-06-04
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT01165112 2018-12-05
TREC
University of Washington
Phase 1/2 Completed
NCT01133158 2018-11-01
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00867503 2018-07-24
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
University of Arizona
Phase 2 Completed
NCT01484626 2018-07-10
BVRD
Loyola University
Phase 1/2 Terminated
NCT02420210 2018-06-06
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
University of Chicago
Phase 2 Terminated
NCT00834678 2018-04-17
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT01315873 2018-02-07
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Phase 2 Terminated
NCT01626352 2017-11-22
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00856830 2017-07-17
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00823797 2017-07-07
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
University of Washington
Phase 2 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed
NCT01234467 2017-05-24
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01056276 2017-05-03
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00705250 2017-03-03
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed